Fig. 3: Cas13a-mediated IAV PB2 RNA knockdown after infection with broadly targeted crRNAs.
From: Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents
a, A549 cells were infected with A/WSN/33. Cells were transfected with Cas13a or Cas13a-NLS and 1:50 mol ratio of WSN33_PB2 or NTCR guides Two-way ANOVA with Sidak’s multiple comparisons, where *P = 0.025, **P = 0.0082, ***P = 0.0005 and ****P < 0.0001. b, A549 cells were infected with A/WSN/33. Twenty-four hpi, cells were transfected with Cas13a or Cas13a-NLS, dead Cas13a, dead Cas13a-NLS mRNA or an equal molar amount of GFP mRNA with a 1:50 mol ratio of WSN33_PB2_g2 or NTCR guides. Two-way ANOVA with Sidak’s multiple comparisons, where *P = 0.0199, **P = 0.0024, ***P = 0.0009 and ****P < 0.0001. c, A549 cells were infected with A/WSN/33. Twenty-four hpi, cells were transfected with Cas13a or Cas13a-NLS, dead Cas13a, dead Cas13a-NLS mRNA or an equal molar amount of GFP mRNA with a 1:50 mol ratio of WSN33_PB2_m4 or NTCR guide. Two-way ANOVA with Sidak’s multiple comparisons, where *P = 0.02, **P = 0.0048 and ***P = 0.0005. Means and standard deviations are shown in gray, with n = 6 biological replicates. WSN/33_PB2 gene copy numbers were normalized by NTCR values. NS, not significant.
